<DOC>
	<DOCNO>NCT01314053</DOCNO>
	<brief_summary>Daptomycin approve since 2005 Taiwan study publish west country . After review publish paper , data describe Asian country Taiwan . The objective study evaluate efficacy safety daptomycin treatment Gram-positive infection actual condition use , understand information concern daptomycin prescription . This study represent opportunity acquire real world data daptomycin usage , may provide physician Taiwan information characteristic patient receive daptomycin evaluate outcome . It also provide mean identify safety signal emerge clinical usage .</brief_summary>
	<brief_title>Retrospective Evaluation Safety Efficacy Daptomycin Used Patients With Serious Gram-positive Infections</brief_title>
	<detailed_description>This retrospective , non-comparative study , perform obtain permission institutional review board . Patients serious gram-positive infection receive daptomycin January 2009 complete daptomycin therapy end December 2010 screen , patient receive â‰¥ 3 day daptomycin identify eligible include . Eligible patient ' medical record review . As retrospective chart review , expect informed consent necessary . For patient ' confidentiality concern , patient ' name chart number record part Data Collection Form ( APPENDIX 1 ) . A patient identification number assign patient include surveillance . A study coordinator site identify , hospital specific process utilized identify patient . Information collect show Data Collection Form ( Appendix 1 ) . After complete patient data collection , efficacy safety evaluate included case .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Patients start daptomycin therapy since January 2009 . Patients complete daptomycin therapy end December 2010 . Patients Gram positive infection . Patients receive daptomycin therapy least 3 day . Daptomycin therapy chosen treat physician base clinical indication expect risk therapy already consider . subject exclude he/she enrol antibiotic clinical trial daptomycin treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Daptomycin</keyword>
	<keyword>Serious Gram-positive Infections</keyword>
</DOC>